Deferasirox for managing iron overload in people with thalassaemia

BACKGROUND: Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long‐term complications. Both deferoxamine...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cochrane Database Syst Rev
Asıl Yazarlar: Bollig, Claudia, Schell, Lisa K, Rücker, Gerta, Allert, Roman, Motschall, Edith, Niemeyer, Charlotte M, Bassler, Dirk, Meerpohl, Joerg J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2017
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6483623/
https://ncbi.nlm.nih.gov/pubmed/28809446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD007476.pub3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller